State Street SPDR S&P Biotech ETF (XBI) ETF Analysis

Fund Overview

State Street SPDR S&P Biotech ETF (XBI) is an exchange-traded fund in the Health category. Total net assets stand at $11.40B. Annual costs run at an expense ratio of 0.35%. On a $10,000 position that is $35.00 a year. State Street Investment Management is the fund family on file. It has been trading since January 31, 2006.

Its biggest positions are Moderna Inc (MRNA), Mirum Pharmaceuticals Inc (MIRM), and Revolution Medicines Inc Ordinary Shares (RVMD). Moderna Inc alone accounts for 1.85% of the portfolio. The ten largest positions together make up 15.08% of the fund.

Performance Analysis

XBI last closed at $163.81 on September 4, 2026. The trailing one-year price return is +75.88%. The stored price history starts on February 7, 2025, and the total return since then is +80.21%. The trailing distribution yield is 0.35%. The provider also reports a 3 years average return of +26.80%.

2026 is still running; the price is +34.35% year to date.

Price & Risk Profile

Daily returns over the trailing 1 year annualize to a volatility of 27.97%. The reported beta is 1.12. Over the past 52 weeks the price has ranged from $92.64 to $169.89. The latest close sits 76.82% above that 52-week low. The volatility figure is calculated from the stored daily closes, the same series the charts on this page use.